Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida”, NASDAQ: PSTX), a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf (also referred to as allogeneic) CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.

Switzerland's Roche (ROG.S) has agreed to pay an initial $7.1 billion to Roivant (ROIV.O) and Pfizer (PFE.N) for rights to a new inflammatory bowel disease drug, as it expands into new fields to offset falling oncology sales.

OmicsEdge and Almaden Genomics said on Thursday that they have partnered on a service to analyze patient genomic data in clinical trials.

Pfizer Inc is planning to raise $31 billion through its largest debt offering to finance its proposed acquisition of Seagen Inc, the drugmaker said late on Tuesday.​

Labcorp, a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.

On January 9, Fosun Foundation, together with Fosun Pharma and Henan Genuine Biotech Co., Ltd., announced that they will donate 100 million yuan worth of oral drug Azvudine to rural areas in China.

Cytiva and Aurisco have cooperated to build Oligo FlexFactory production line project in Yangzhou. This production base has been invested hundreds of millions of yuan and can reach an annual production capacity of hundreds of kilograms of GMP-level small nucleic acid drugs once established.

Roche and Pfizer have launched a collaboration in the U.S. to help those who test positive for COVID-19 find the best resources for the best possible outcomes.

Recently, Shenzhen Superbio Technology Co., Ltd. Fentanyl Drug Abuse Detection Kit (fluorescence chromatography method) has obtained 510 (k) pre-market notification, which is the world's first POCT product approved by the US FDA for the detection of fentanyl by fluorescence method.

Bioinformatics company Envisagenics said Tuesday that it has formed a research collaboration with Queen Mary University of London and the technology-transfer arm of Cancer Research UK to explore the role of "alternative" splicing in hematopoietic cancer.